Muscarinic acetylcholine receptors for psychotic disorders req reading

Overview of Muscarinic Acetylcholine Receptors (mAChRs) in Schizophrenia

  • mAChR activators, particularly xanomeline, showed unexpected antipsychotic activity for schizophrenia starting in the 1990s.

  • Targeted ligands and combination treatments have improved tolerability and efficacy.

Key mAChR Subtypes and Their Functions

  • Main mAChR subtypes in the central nervous system (CNS): M1 and M4.

  • M1 receptor: Excitatory; M4 receptor: Inhibitory.

  • mAChRs modulate various physiological functions via second-messenger signaling pathways.

Implications for Psychotic Disorders

  • Effective control of positive symptoms is crucial for treating schizophrenia.

  • Agonists for M1 and M4 receptors can aid in antipsychotic effects without targeting dopamine receptors directly.

  • Peripheral activation of mAChRs typically contributes to adverse effects; strategies exist to minimize these through selective targeting.

Advances in Drug Development

  • Dual M1/M4 agonists and selective M4 PAMs (positive allosteric modulators) are in clinical development.

  • Notable candidates: KarXT (xanomeline + trospium) and emraclidine (CVL-231).

  • KarXT demonstrated significant efficacy in Phase 2 and Phase 3 trials for schizophrenia.

Theoretical Background and Research Gaps

  • Understanding the pharmacological role of mAChR subtypes to optimize therapeutic effects and minimize side effects remains a key area of research.

  • Addressing the balance between efficacy and tolerability is vital due to the complex signaling pathways involved.

Conclusion and Future Directions

  • mAChR activators represent a promising new class for treating schizophrenia, particularly for cognitive and negative symptoms.

  • Ongoing studies aim to elucidate the specific roles of mAChR subtypes and improve drug design for future therapies.